in this eye-opening episode we venture into the world of pediatric oncology, where the faces behind the heartrending commercials reveal a poignant truth- while pediatric cancer is an undeniable reality, the journey to access innovative treatments in canada is fraught with challenges. in this episode, i speak to keith mcintosh from ac2orn in a candid conversation that transcends the surface-level awareness of pediatric cancer, delving into the complexities that hinder progress in pediatric oncology care.

in this episode, anris kica discusses into the critical need for patient-centric approaches in cancer care and clinical research, exploring the complexities of regulatory processes and health technology assessments. join us as we navigate the fine balance between optimism and frustration, discussing the urgency of accessing life-saving therapies for those in desperate need. uncover the challenges that hinder our ability to provide timely solutions and discover the collective efforts required to revolutionize the landscape of cancer treatment in canada.

in this episode we explore the paraadigm shift towards patient centricity in clinical trials. we discuss the transformative impact of putting patients at the heart of the research process. barry stein discusses why we need patient-centric clinical trials, how they can redefine the way studies are designed, conducted, and evaluated. and what this means for the pharmaceutical industry and most importantly for patients.

n this episode of colab.conversations lisa machado discusses the power of the patient voice, and exploring ways to embolden decision-makers to pioneer a healthcare system that truly caters to patients' needs. from bravery in decision-making to unwavering support for patient advocates, this episode rethinks a patient-centric future.

in this episode, we dive deep into the world of oncology and explore the crucial topic of endpoints beyond overall survival (OS) and their pivotal role in health technology assessment (HTA). our guest, bob bick will provide background on how these alternative endpoints are reshaping the landscape of cancer research, and how this will impact health technology assessment. we'll examine the far-reaching implications of this paradigm shift. don't miss this insightful conversation that sheds light on the evolving standards of cancer care.

in this episode, we delve into a thought provoking conversation with Louise Binder, an advocate who began her journey in the HIV space. drawing insights from the roots of patient advocacy in the HIV community, we navigate the intricate distinctions between advocacy and activism and louise shares invaluable perspectives on how HIV advocates successfully spearheaded transformative changes for patients. we explore the nuances between advocacy and activism while addressing the question of why some may argue that cancer is perceived as less important to cure than HIV.